RETEVMO — ELI LILLY AND CO, approved 2026-07-14 (NDA218160).
849 reports across the top reactions. These are spontaneously reported events from the FDA Adverse Event Reporting System — they reflect reporting volume, not incidence or frequency, and a report does not mean the drug caused the event.